| ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in NHP model and 91% more relative weight loss than petrelintide in DIO rat model | The 33rd European Congress on Obesity
(ECO 2026) | Poster |
5/2026 |
| ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, demonstrated 14-day average observed half-life, 6-fold longer than tirzepatide, in NHP model and 71% more relative weight loss than tirzepatide in DIO mouse model | The 33rd European Congress on Obesity
(ECO 2026) | Poster |
5/2026 |
| ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy | The 33rd European Congress on Obesity
(ECO 2026) | Poster |
5/2026 |
| GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice | ObesityWeek® 2025 | Poster |
11/2025 |
| A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity | ObesityWeek® 2025 | Poster |
11/2025 |
| ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity:A Ph Ib Study | ObesityWeek® 2025 | Poster |
11/2025 |
| ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study | The 61st European Association for the Study of Diabetes
(EASD 2025) | Short Oral Presentation |
9/2025 |
| ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model | The American Diabetes Association's 85th Scientific Sessions
(ADA 2025) | Poster |
6/2025 |
| ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study | The American Diabetes Association's 85th Scientific Sessions
(ADA 2025) | Poster |
6/2025 |
| ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study | The 32nd European Congress On Obesity (ECO 2025) | Guided poster |
5/2025 |
| ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice | The 32nd European Congress On Obesity (ECO 2025) | Oral |
5/2025 |
浙公网安备 33010802003344号 浙ICP备11050387号-1